Permanent Iodine-125 Seed Implantation for the Treatment of Nonresectable Retroperitoneal Malignant Tumors

Li, Qingchun; Tian, Yuan; Yang, Dejun; Liang, Yun; Cheng, Xianbin; Gai, Baodong

doi:10.1177/1533033819825845

Cited by 11 publications

(10 citation statements)

References 17 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…125 I brachytherapy is known to be safe and effective in advanced cancer patients (11)(12)(13)(14)(15)(16)(17), and the multiple-needle parallel puncture method is the most common and widely used treatment regimen for 125 I brachytherapy (11)(12)(13)(14)(15)(16)(17)37). It requires multiple accessible puncture sites without obstruction, and is suitable for tumors with relatively regular shapes.…”

Section: Discussionmentioning

confidence: 99%

“…Computerized tomography (CT)-guided local radioactive Idione-125 ( 125 I) seed brachytherapy has been widely used for various types of advanced cancers, including lung cancer, uveal melanoma, breast cancer, malignant gliomas and retroperitoneal malignant tumors (11)(12)(13)(14)(15)(16)(17). Treatment planning systems (TPS) are employed in CT-guided local radioactive 125 I seed brachytherapy to ensure that the tumor site receives the maximum therapeutic dose while sparing surrounding tumor tissue, which represents one of the most effective approaches for maximum clinical benefit to the patient (18,19).…”

Section: Introductionmentioning

confidence: 99%

“…I brachytherapy induces rapid tumor regression (Figure 1D) (11)(12)(13)(14)(15)(16)(17), but the pathological feature of irradiated tumor cells remains poorly defined. We thus assessed pathological alterations in tumor tissues from eight patients before and after SNCP-125 I brachytherapy.…”

mentioning

confidence: 99%

See 2 more Smart Citations

A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy

Wang

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPatients with progressive thoracic malignancy characterized by large irregular tumors with necrosis and life-threatening symptoms lack effective treatments. We set out to develop a single needle cone puncture method for the Iodine-125 seed (SNCP-125I) brachytherapy, and aim to report the initial results.Methods294 patients with advanced thoracic malignancy were treated with local SNCP-125I brachytherapy between March 2009 and July 2020, followed by thorough evaluation of clinical outcome, overall survival (OS), progression-free survival (PFS) and procedure-related complications after treatment.ResultsThe overall response rate (ORR) among the treated patients was 81.0% (238/294). Life-threatening symptoms due to tumor oppression, hemoptysis and large irregular tumor with necrosis were successfully alleviated after the SNCP-125I treatment with a remission rate at 91% to 94%. The median OS and PFS were 13.6 months and 5.8 months, respectively. Procedure-related side effects including pneumothorax (32/294), blood-stained sputum (8/294), subcutaneous emphysema (10/294), puncture site bleeding (16/294) and chest pain (6/294) were observed. Patients who were able to follow with chemotherapy or immunotherapy experienced extended OS and PFS, as compared with patients who opted to receive hospice care (16.5 months Vs. 11.2 months). Further pathological and immunological analysis showed that SNCP-125I induced tumor lymphocytes infiltration and long-term tumor necrosis.ConclusionSNCP-125I brachytherapy effectively eliminates life-threatening symptoms due to local tumor oppression, hemoptysis and large irregular and necrotic tumors in patients with unresectable chest malignancy and significantly induces local tumor regression. SNCP-125I brachytherapy combines with chemotherapy significantly prolong OS and PFS compare with SNCP-125I brachytherapy alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy

Wang

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Iodine-125 radioactive seeds can be implanted into the tumor permanently and release continuous low-dose X- and γ-rays that provide steady irradiation to the tumor cells at all stages of the cell cycle, with only a negligible radiation dose to the normal tissues adjacent to the lesion [ 9 ] . It had been shown that iodine -125 seed implantation is a highly effective treatment for patients with primary and secondary tumors of any body system [ 9 , 10 ] . The advantages of brachytherapy in the treatment of malignant tumors include:…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer

Yunchao

Yin

Jia³

et al. 2020

Medicine

View full text Add to dashboard Cite

Introduction: Apatinib is a novel anti-angiogenic agent that targets vascular endothelial growth factor receptor-2, and is effective in patients with advanced lung cancer who are refractory to first-line chemotherapy. However, there are limited reports on concurrent apatinib therapy with iodine-125 radioactive seeds brachytherapy in elderly patients with advanced lung cancer. Patient concerns: We describe the first reported case of a 70-year-old woman with advanced lung cancer (T3N3M1, stage IV) who received concurrent apatinib and iodine-125 radioactive seeds brachytherapy after the failure of platinum-based doublet chemotherapy Diagnosis: The patient was diagnosed with left lower lung cancer with mediastinal lymph node metastasis by chest computed tomography. Interventions: Initially, apatinib alone was used as second-line cancer therapy. Subsequently, the patient received concurrent apatinib and iodine-125 radioactive seeds brachytherapy. Outcomes: The patient achieved partial response shortly after undergoing treatment with only apatinib. During the treatment, the tumor continued to respond to apatinib therapy, and the lung metastases were diminished eventually. However, a chest computed tomography scan showed a large cavity in the lung tumor. Thereafter, the patient received concurrent apatinib and iodine-125 radioactive seeds brachytherapy. Unfortunately, she died due to pulmonary infection. Conclusion: Apatinib alone may be a good second-line therapy for advanced lung cancer patients who are refractory to platinum-based doublet chemotherapy. However, its potential benefits, especially as combination therapy, need further investigation by future prospective clinical studies. Elderly patients with advanced lung cancer may benefit from concurrent apatinib with iodine-125 radioactive seeds brachytherapy when chemotherapy is not tolerated or effective. Further studies are needed to investigate the clinical outcomes and toxicities associated with concurrent apatinib and radiation therapy in patients with advanced lung cancer.

show abstract

“… 6 125I seeds have been shown to be effective in killing tumor cells without causing significant damage to the surrounding normal tissues. 7 125I seeds and postoperatively chemotherapy treatment in locally advanced pancreatic cancer has a better effect than chemotherapy alone . Patient complications and the OS life cycle increased.…”

Section: Introductionmentioning

confidence: 99%

125I Intracavitary Irradiation Combined with 125I Seeds Implantation for Treatment of Locally Advanced Pancreatic Head Cancer: A Retrospective Analysis of 67 Cases

Zhou¹,

Zhu²,

Chen³

et al. 2021

IJGM

View full text Add to dashboard Cite

Background Pancreatic cancer is an aggressive malignant tumor of the digestive system and the fourth leading cause of tumor-related death. Intracavitary 125 I seed irradiation has been recently developed as a therapy for locally advanced pancreatic head carcinoma. However, there are still many limitations, and more investigations are needed in order to optimize this new treatment method. Methods Sixty-seven patients were included in our study; 41 cases treated by SEMS-CL- 125 I intracavular irradiation (SEMS-CL- 125 I group) and 26 cases treated by SEMS-CL- 125 I intracavular irradiation combined with 125 I particle implantation in the tumor body (the combined group). Among the 67 patients, 43 were males and 24 were females, with an average age of 69.64±8.84 years. Tumor site size was determined based on the MRI or CT imaging scans, and the number and radius of 125 I particle placement were calculated according to a specific formula. 125 I particles were inserted into the tumor with a radius of 1.5 cm and a row spacing of 1 cm. The main postoperative biochemical indexes, imaging analysis, postoperative analgesia degree, median survival time and rate of complications were compared between the two groups. Results Jaundice and liver function improved in both groups after treatment for 6 months. The combined group did better. Kaplan–Meier analysis showed that patients in the combined group had a significantly better overall survival than those in the SEMS-CL- 125 I group. Patients in the combined group had less complications than those in the SEMS-CL- 125 I group (23.1% vs 34.1%), and the postoperative pain status of the combined group was improved (26.8% vs 53.8%). Conclusion Compared with the SEMS-CL- 125 I intracavular irradiation alone, the combination of 125 I seed implantation with solid tumor 125 I seed implantation had a better therapeutic effect in LAPHC patients, with improved biochemical indicators, survival prognosis, pain relief, and fewer complications.

show abstract

Permanent Iodine-125 Seed Implantation for the Treatment of Nonresectable Retroperitoneal Malignant Tumors

Cited by 11 publications

References 17 publications

A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy

A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy

Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer

125I Intracavitary Irradiation Combined with 125I Seeds Implantation for Treatment of Locally Advanced Pancreatic Head Cancer: A Retrospective Analysis of 67 Cases

Contact Info

Product

Resources

About